Literature DB >> 3724747

Selection of nitrogen mustard resistance in a rat tumor cell line results in loss of guanine-O6-alkyl transferase activity.

S W Dean, N W Gibson, K D Tew.   

Abstract

Cell killing, DNA-interstrand crosslinks, and DNA-protein crosslinks were assayed in nitrogen mustard-resistant Walker 256 carcinoma (WR) cells and the parent cell line (WS) after treatment with 5-[3-(2-chloroethyl)-1-triazenyl]imidazo-4-carboxamide (MCTIC). The WR cells, which also express collateral sensitivity to chloroethylnitrosoureas, were approximately twice as sensitive to the cytotoxic effects of MCTIC as were WS cells. Following treatment with 100 microM MCTIC, there was a rapid accumulation of both DNA-interstrand and DNA-protein crosslinks in the WR cell line, which reached a maximum at 6 and 12 hr, respectively. There was considerably less crosslinking in the WS cells and both cell lines were proficient in repairing most of the crosslinks by 24 hr. Measurement of guanine-O6-alkyl transferase activity showed the enzyme to be present in WS but not in WR cells. These data indicate that the collateral sensitivity of nitrogen mustard-resistant WR cells to chloroethylating drugs is in part due to the loss of guanine-O6-alkyl transferase activity which is present in the parent line.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3724747

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  2 in total

1.  The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines.

Authors:  K D Tew; S W Dean; N W Gibson
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

Authors:  Helen M Coley; Eleftheria Hatzimichael; Sarah Blagden; Iain McNeish; Alastair Thompson; Tim Crook; Nelofer Syed
Journal:  Oncotarget       Date:  2012-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.